Patents Assigned to National Cancer Center
  • Computer-readable recording medium having stored therein information processing program, method for processing information, and information processing apparatus
    Patent number: 11508064
    Abstract: A method includes: acquiring a training data set including pieces of training data, each of the pieces including an image of a training target, first annotation data representing a rectangular region in the image, and second annotation data; training, based on the image and the first annotation data, an object detection model specifying a rectangular region including the training target; training, based on the image and the second annotation data, a neural network; and calculating a first index value related to a relationship of a pixel number, the trained estimation model and the calculated first index value being used in a determination process that determines, based on the calculated first index value and a second index value relationship between a pixel number in an output result and an estimation result, whether or not a target in a target image is normal.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: November 22, 2022
    Assignees: FUJITSU LIMITED, RIKEN, NATIONAL CANCER CENTER
    Inventors: Akira Sakai, Masaaki Komatsu, Ai Dozen
  • Biliary tract cancer detection kit or device, and detection method
    Patent number: 11499198
    Abstract: The present invention provides a kit or device for the detection of biliary tract cancer, and a method for detecting biliary tract cancer. The present invention relates to a kit or device for the detection of biliary tract cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting biliary tract cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: November 15, 2022
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei Kawauchi, Hitoshi Nobumasa, Satoko Kozono, Satoshi Kondou, Hiroko Sudo, Atsushi Ochiai, Motohiro Kojima
  • Stomach cancer detection kit or device, and detection method
    Patent number: 11486009
    Abstract: This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: November 1, 2022
    Assignees: Toray Industries, Inc., National Cancer Center
    Inventors: Satoko Kozono, Hitoshi Nobumasa, Satoshi Kondou, Hiroko Sudo, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
  • Breast cancer detection kit or device, and detection method
    Patent number: 11479822
    Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: October 25, 2022
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoshi Kondou, Hitoshi Nobumasa, Satoko Kozono, Hiroko Sudo, Junpei Kawauchi, Takahiro Ochiya, Nobuyoshi Kosaka, Makiko Ono, Kenji Tamura
  • Colorectal cancer detection kit or device, and detection method
    Patent number: 11479821
    Abstract: It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: October 25, 2022
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Satoko Kozono, Hitoshi Nobumasa, Satoshi Kondou, Hiroko Sudo, Junpei Kawauchi, Atsushi Ochiai, Motohiro Kojima
  • Body-insertable device having adjustable radiation emission direction and radiation emission range
    Patent number: 11471701
    Abstract: A body-insertable device having an adjustable radiation emission direction and radiation emission range, which includes a first outer body extending to be long and an accommodation space having a first accommodation space and a second accommodation space having different distances to the first outer body.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: October 18, 2022
    Assignee: NATIONAL CANCER CENTER
    Inventors: Young Kyung Lim, Ui Jung Hwang, Young Moon Goh, Hak Soo Kim, Dong Ho Shin, Se Byeong Lee, Jong Hwi Jeong, Joo Young Kim, Tae Hyun Kim
  • PROBE, PACKAGE PROBE, EXTERNAL DEVICE CONNECTOR, AND BIOFEEDBACK DEVICE
    Publication number: 20220322990
    Abstract: A probe includes an insertion portion insertable into a body organ, a projecting portion being exposed to an outside of a body after the insertion portion is inserted into the body organ, a device mounting area onto which an external-device coupler is removably mountable, and sensing electrodes provided on the insertion portion and the device mounting area. When the insertion portion is inserted into the body organ, the sensing electrodes detect a biosignal and become conductive with coupling electrodes of the external-device coupler mounted onto the device mounting area. The probe is an electromyograph probe that detects a biosignal measurable by an electromyograph. The insertion portion and the projecting portion of the probe may be integrated or separate from each other. Both of the insertion portion and the projecting portion or only the insertion portion may be disposable.
    Type: Application
    Filed: April 3, 2020
    Publication date: October 13, 2022
    Applicants: SOFKEN CO., LTD., NATIONAL CANCER CENTER
    Inventors: Yuji NISHIZAWA, Takeo KOMAMURA, Kenzo KOMAMURA
  • Carcinogenesis inhibitor
    Patent number: 11464762
    Abstract: A carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: October 11, 2022
    Assignees: NATIONAL CANCER CENTER, NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Michihiro Mutoh, Yurie Kurokawa, Gen Fujii, Shingo Miyamoto
  • COMBINATION THERAPY AND BIOMARKER INDICATING EFFICACY THEREOF
    Publication number: 20220304972
    Abstract: The present disclosure provides a method for treating a microsatellite stable cancer patient with a specific combination of medical agents or a composition or combination therefor. Specific combinations of medical agents include a combination of a cancer stem cell inhibitor (e.g., napabucasin) and an immune checkpoint inhibitor (e.g., pembrolizumab). The MSS patient can be selected by determining if the patient has one or more patient characteristics. Another aspect of the disclosure provides a method for predicting responsiveness of a patient to a cancer treatment based on one or more patient characteristics.
    Type: Application
    Filed: August 21, 2020
    Publication date: September 29, 2022
    Applicants: Sumitomo Dainippon Pharma Co., Ltd., National Cancer Center
    Inventors: Takayuki YOSHINO, Yasutoshi KUBOKI, Akihito KAWAZOE
  • KIT OR DEVICE FOR DETECTING EARLY STAGE PANCREATIC CANCER OR PANCREATIC CANCER PRECURSOR LESIONS AND DETECTION METHOD THEREFOR
    Publication number: 20220290256
    Abstract: This application provides a kit or a device for the detection of early pancreatic cancer or a pancreatic cancer precursor lesion, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting early pancreatic cancer or a pancreatic cancer precursor lesion, comprising measuring an expression level(s) of the miRNA(s) in vitro.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 15, 2022
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei KAWAUCHI, Hiroko SUDO, Satoko KOZONO, Atsushi OCHIAI, Motohiro KOJIMA
  • BIOMARKERS FOR DETERMINING THE EFFICACY OF IMMUNE CHECKPOINT INHIBITORS
    Publication number: 20220283167
    Abstract: A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.
    Type: Application
    Filed: August 4, 2020
    Publication date: September 8, 2022
    Applicants: ONO PHARMACEUTICAL CO., LTD., NATIONAL CANCER CENTER
    Inventors: Hiroyoshi NISHIKAWA, Yukiya OHYAMA, Atsushi HONDA, Atsushi OYAGI, Toru KAKINUMA, Masayuki MURATA
  • Image analysis method, image analysis apparatus, program, learned deep layer learning algorithm manufacturing method and learned deep layer learning algorithm
    Patent number: 11436718
    Abstract: An image analysis method for generating data indicating a tumorigenic state of an image of a tissue or a cell. The image analysis method is an image analysis method for analyzing an image of a tissue or a cell using a deep learning algorithm of a neural network structure, analysis data are generated from the analysis target image including a tissue or cell to be analyzed, the analysis data are input to the deep learning algorithm, and data indicating the tumorigenic state of tissues or cells in the analysis target image are generated by the depth learning algorithm.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: September 6, 2022
    Assignees: NATIONAL CANCER CENTER, SYSMEX CORPORATION
    Inventors: Hiroshi Yoshida, Yosuke Sekiguchi, Kazumi Hakamada, Yuki Aihara, Kohei Yamada, Kanako Masumoto, Krupali Jain
  • KIT, DEVICE, AND METHOD FOR DETECTING BLADDER CANCER
    Publication number: 20220275449
    Abstract: An embodiment according to the present invention provides a kit or device for detection of bladder cancer, and a method for detecting bladder cancer. An embodiment according to the present invention relates to: a kit or device for detection of bladder cancer, including a nucleic acid(s) capable of specifically binding to an miRNA(s) or a complementary strand(s) thereof in a sample from a subject; and a method for detecting bladder cancer, including measuring the miRNA(s) in vitro.
    Type: Application
    Filed: April 25, 2019
    Publication date: September 1, 2022
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Makiko YOSHIMOTO, Hiroko SUDO, Satoko KOZONO, Junpei KAWAUCHI, Takahiro OCHIYA, Hiroyuki FUJIMOTO, Wataru USUBA, Juntaro MATSUZAKI
  • METHOD FOR ASSISTING DETERMINATION OF EXACERBATION RISK OF COVID-19
    Publication number: 20220268786
    Abstract: Disclosed is a method for acquiring information on exacerbation risk of COVID-19, comprising measuring IgM antibody against S antigen of SARS-CoV-2 contained in a specimen collected from a subject infected with SARS-CoV-2 or a subject suspected of suffering from COVID-19, wherein a value obtained by the measurement of IgM antibody serves as an index of exacerbation risk of COVID-19 of the subject.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 25, 2022
    Applicants: NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, NATIONAL CANCER CENTER, SYSMEX CORPORATION
    Inventors: Hiroaki MITSUYA, Kenji MAEDA, Akinobu HAMADA, Kenta NODA, Kazuto YAMASHITA, Yusuke ATARASHI, Nobuyuki IDE
  • NOVEL DNA APTAMERS AND USE THEREOF
    Publication number: 20220259598
    Abstract: The present disclosure relates to novel DNA aptamers and use thereof. In particular, the present disclosure relates to DNA aptamers selected from a DNA library using Cell-SELEX to bind specifically to cancer cells. The DNA aptamers of the present disclosure selected and optimized for high binding affinity to cancer cells can be effectively used for the diagnosis of cancer as they have enhanced targeting efficiencies for target cells and tissues.
    Type: Application
    Filed: July 19, 2019
    Publication date: August 18, 2022
    Applicants: NATIONAL CANCER CENTER, JP BIO A INC.
    Inventors: Yun Hee KIM, Kyun HEO, Sun II CHOI, In Hoo KIM
  • Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
    Patent number: 11377504
    Abstract: The present invention provides an antibody beneficial for treatment of a solid tumor, an antibody-drug conjugate thereof, and an anticancer agent comprising these. The present invention provides, for example, an antibody that binds to tissue factor or an antigen-binding fragment thereof, wherein the antibody has a dissociation rate constant kd of 5×10?4 s?1 or more and an association rate constant Ka of 1×104 M?1 s?1 or more.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: July 5, 2022
    Assignees: National Cancer Center Japan, RIN Institute Inc.
    Inventors: Yasuhiro Matsumura, Masahiro Yasunaga, Shinji Saijo, Ryo Tsumura
  • Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor
    Patent number: 11365449
    Abstract: This application provides a kit or a device for the detection of early pancreatic cancer or a pancreatic cancer precursor lesion, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting early pancreatic cancer or a pancreatic cancer precursor lesion, comprising measuring an expression level(s) of the miRNA(s) in vitro.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 21, 2022
    Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Junpei Kawauchi, Hiroko Sudo, Satoko Kozono, Atsushi Ochiai, Motohiro Kojima
  • Nanostructure for detecting cell-free DNA using conductive polymer and the use thereof
    Patent number: 11352616
    Abstract: Disclosed is a structure for detecting cell-free DNA using a conductive polymer and the use thereof. More particularly, a nanostructure composed of a surface-modified conductive polymer for isolating and detecting cell-free DNA is disclosed. By using the nanostructure, cell-free DNA including circulating tumor DNA, can be effectively detected and isolated.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 7, 2022
    Assignee: NATIONAL CANCER CENTER
    Inventors: Youngnam Cho, Eun Sook Lee
  • KIT, DEVICE, AND METHOD FOR DETECTING UTERINE LEIOMYOSARCOMA
    Publication number: 20220136067
    Abstract: This invention provides a kit and device for detection of uterine leiomyosarcoma, and a method for detecting uterine leiomyosarcoma. This invention provides a kit and device for detection of uterine leiomyosarcoma containing a nucleic acid capable of specifically binding to a miRNA in a sample from a subject or a complementary strand thereof and a method for detecting uterine leiomyosarcoma including measuring the miRNA in vitro.
    Type: Application
    Filed: March 6, 2020
    Publication date: May 5, 2022
    Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTER
    Inventors: Makiko YOSHIMOTO, Satoko KOZONO, Takahiro OCHIYA, Tomoyasu KATO, Akira YOKOI, Juntaro MATSUZAKI
  • Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
    Patent number: 11311626
    Abstract: The present invention relates to an antibody-drug conjugate (ADC) and a composition containing the conjugate for use in treating cancer. According to the present invention, provided are an ADC of an antibody specific to insoluble fibrin and a drug in which a linker linking the antibody and the drug has a plasmin cleavage sequence, and a pharmaceutical composition containing the ADC for use in treating cancer.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 26, 2022
    Assignees: NATIONAL CANCER CENTER JAPAN, RIN INSTITUTE INC.
    Inventors: Yasuhiro Matsumura, Shino Manabe, Hirobumi Fuchigami